CN103704711B - Granules with anti-fatigue and health-care function - Google Patents
Granules with anti-fatigue and health-care function Download PDFInfo
- Publication number
- CN103704711B CN103704711B CN201310754441.6A CN201310754441A CN103704711B CN 103704711 B CN103704711 B CN 103704711B CN 201310754441 A CN201310754441 A CN 201310754441A CN 103704711 B CN103704711 B CN 103704711B
- Authority
- CN
- China
- Prior art keywords
- beta
- group
- product
- fatigue
- creatine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 230000002929 anti-fatigue Effects 0.000 title claims abstract description 19
- 239000008187 granular material Substances 0.000 title abstract description 7
- 239000000203 mixture Substances 0.000 claims description 32
- 230000001954 sterilising effect Effects 0.000 claims description 8
- 239000012467 final product Substances 0.000 claims 2
- CVSVTCORWBXHQV-UHFFFAOYSA-N creatine Chemical compound NC(=[NH2+])N(C)CC([O-])=O CVSVTCORWBXHQV-UHFFFAOYSA-N 0.000 abstract description 64
- 108090000623 proteins and genes Proteins 0.000 abstract description 36
- 102000004169 proteins and genes Human genes 0.000 abstract description 36
- 239000000843 powder Substances 0.000 abstract description 35
- 229960003624 creatine Drugs 0.000 abstract description 32
- 239000006046 creatine Substances 0.000 abstract description 32
- 230000000694 effects Effects 0.000 abstract description 25
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 abstract description 22
- 229930091371 Fructose Natural products 0.000 abstract description 13
- 239000005715 Fructose Substances 0.000 abstract description 13
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 abstract description 13
- 229960003080 taurine Drugs 0.000 abstract description 11
- 244000131316 Panax pseudoginseng Species 0.000 abstract description 9
- 235000003181 Panax pseudoginseng Nutrition 0.000 abstract description 9
- 240000005373 Panax quinquefolius Species 0.000 abstract description 9
- 235000003140 Panax quinquefolius Nutrition 0.000 abstract description 9
- 238000011084 recovery Methods 0.000 abstract description 5
- 241000007126 Codonopsis pilosula Species 0.000 abstract description 3
- 208000002720 Malnutrition Diseases 0.000 abstract description 2
- 230000001071 malnutrition Effects 0.000 abstract description 2
- 235000000824 malnutrition Nutrition 0.000 abstract description 2
- 208000015380 nutritional deficiency disease Diseases 0.000 abstract description 2
- 241001632410 Eleutherococcus senticosus Species 0.000 abstract 1
- WLJUMPWVUPNXMF-UHFFFAOYSA-L calcium;3-hydroxy-3-methylbutanoate Chemical compound [Ca+2].CC(C)(O)CC([O-])=O.CC(C)(O)CC([O-])=O WLJUMPWVUPNXMF-UHFFFAOYSA-L 0.000 abstract 1
- 239000000047 product Substances 0.000 description 48
- 235000018102 proteins Nutrition 0.000 description 35
- 241000699666 Mus <mouse, genus> Species 0.000 description 29
- 239000003814 drug Substances 0.000 description 20
- 210000004369 blood Anatomy 0.000 description 18
- 239000008280 blood Substances 0.000 description 18
- 244000197580 Poria cocos Species 0.000 description 12
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 12
- 235000008599 Poria cocos Nutrition 0.000 description 11
- 241000700159 Rattus Species 0.000 description 10
- 238000003304 gavage Methods 0.000 description 10
- 150000004676 glycans Chemical class 0.000 description 10
- 229920001282 polysaccharide Polymers 0.000 description 10
- 239000005017 polysaccharide Substances 0.000 description 10
- 210000000952 spleen Anatomy 0.000 description 10
- 241000756943 Codonopsis Species 0.000 description 9
- 239000000463 material Substances 0.000 description 9
- 244000046146 Pueraria lobata Species 0.000 description 8
- 235000010575 Pueraria lobata Nutrition 0.000 description 8
- 239000007864 aqueous solution Substances 0.000 description 8
- 229940079593 drug Drugs 0.000 description 8
- 230000009182 swimming Effects 0.000 description 8
- 235000018167 Reynoutria japonica Nutrition 0.000 description 7
- 240000001341 Reynoutria japonica Species 0.000 description 7
- 238000002474 experimental method Methods 0.000 description 7
- 210000003205 muscle Anatomy 0.000 description 7
- 235000016709 nutrition Nutrition 0.000 description 7
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 6
- 239000008103 glucose Substances 0.000 description 6
- 239000004310 lactic acid Substances 0.000 description 6
- 235000014655 lactic acid Nutrition 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- 239000002504 physiological saline solution Substances 0.000 description 6
- 235000000346 sugar Nutrition 0.000 description 6
- 235000019640 taste Nutrition 0.000 description 6
- 210000001541 thymus gland Anatomy 0.000 description 6
- ZKHQWZAMYRWXGA-KQYNXXCUSA-N Adenosine triphosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-N 0.000 description 5
- 229920002527 Glycogen Polymers 0.000 description 5
- 238000012449 Kunming mouse Methods 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- 235000013305 food Nutrition 0.000 description 5
- 229940096919 glycogen Drugs 0.000 description 5
- 210000004185 liver Anatomy 0.000 description 5
- 230000005855 radiation Effects 0.000 description 5
- 210000002966 serum Anatomy 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 241000699670 Mus sp. Species 0.000 description 4
- 241000180649 Panax notoginseng Species 0.000 description 4
- 235000003143 Panax notoginseng Nutrition 0.000 description 4
- 102000019197 Superoxide Dismutase Human genes 0.000 description 4
- 108010012715 Superoxide dismutase Proteins 0.000 description 4
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 4
- PNNCWTXUWKENPE-UHFFFAOYSA-N [N].NC(N)=O Chemical compound [N].NC(N)=O PNNCWTXUWKENPE-UHFFFAOYSA-N 0.000 description 4
- HIMXGTXNXJYFGB-UHFFFAOYSA-N alloxan Chemical compound O=C1NC(=O)C(=O)C(=O)N1 HIMXGTXNXJYFGB-UHFFFAOYSA-N 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 230000007062 hydrolysis Effects 0.000 description 4
- 238000006460 hydrolysis reaction Methods 0.000 description 4
- 230000036039 immunity Effects 0.000 description 4
- 210000004165 myocardium Anatomy 0.000 description 4
- 235000015097 nutrients Nutrition 0.000 description 4
- 230000035764 nutrition Effects 0.000 description 4
- 239000013641 positive control Substances 0.000 description 4
- 238000005507 spraying Methods 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 108010076119 Caseins Proteins 0.000 description 3
- 239000009759 San-Chi Substances 0.000 description 3
- 238000009825 accumulation Methods 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 230000034994 death Effects 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 230000003203 everyday effect Effects 0.000 description 3
- 239000000796 flavoring agent Substances 0.000 description 3
- 235000019634 flavors Nutrition 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 210000002216 heart Anatomy 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 230000033001 locomotion Effects 0.000 description 3
- 230000004060 metabolic process Effects 0.000 description 3
- 239000001301 oxygen Substances 0.000 description 3
- 229910052760 oxygen Inorganic materials 0.000 description 3
- 230000007170 pathology Effects 0.000 description 3
- 230000001737 promoting effect Effects 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 239000006188 syrup Substances 0.000 description 3
- 231100000331 toxic Toxicity 0.000 description 3
- 230000002588 toxic effect Effects 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 206010007247 Carbuncle Diseases 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 208000032843 Hemorrhage Diseases 0.000 description 2
- 206010021143 Hypoxia Diseases 0.000 description 2
- 241001529936 Murinae Species 0.000 description 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 2
- 241000219780 Pueraria Species 0.000 description 2
- 206010070863 Toxicity to various agents Diseases 0.000 description 2
- 240000008042 Zea mays Species 0.000 description 2
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 2
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 2
- 230000007059 acute toxicity Effects 0.000 description 2
- 231100000403 acute toxicity Toxicity 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 208000034158 bleeding Diseases 0.000 description 2
- 230000000740 bleeding effect Effects 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 210000001124 body fluid Anatomy 0.000 description 2
- 239000010839 body fluid Substances 0.000 description 2
- 239000004202 carbamide Substances 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 230000000747 cardiac effect Effects 0.000 description 2
- 239000005018 casein Substances 0.000 description 2
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 2
- 235000021240 caseins Nutrition 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 230000004087 circulation Effects 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- 235000005822 corn Nutrition 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 239000003651 drinking water Substances 0.000 description 2
- 235000020188 drinking water Nutrition 0.000 description 2
- 230000002526 effect on cardiovascular system Effects 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- 229940089161 ginsenoside Drugs 0.000 description 2
- 229930182494 ginsenoside Natural products 0.000 description 2
- 230000023597 hemostasis Effects 0.000 description 2
- 230000002440 hepatic effect Effects 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 210000004731 jugular vein Anatomy 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000002207 metabolite Substances 0.000 description 2
- 235000013336 milk Nutrition 0.000 description 2
- 239000008267 milk Substances 0.000 description 2
- 210000004080 milk Anatomy 0.000 description 2
- 238000000465 moulding Methods 0.000 description 2
- 208000031225 myocardial ischemia Diseases 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- NHZMQXZHNVQTQA-UHFFFAOYSA-N pyridoxamine Chemical compound CC1=NC=C(CO)C(CN)=C1O NHZMQXZHNVQTQA-UHFFFAOYSA-N 0.000 description 2
- 238000011552 rat model Methods 0.000 description 2
- 230000035807 sensation Effects 0.000 description 2
- 235000019615 sensations Nutrition 0.000 description 2
- 210000000697 sensory organ Anatomy 0.000 description 2
- 239000002002 slurry Substances 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 235000019605 sweet taste sensations Nutrition 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 238000012549 training Methods 0.000 description 2
- 241000251468 Actinopterygii Species 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 241000208340 Araliaceae Species 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 241000282461 Canis lupus Species 0.000 description 1
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 description 1
- 208000034656 Contusions Diseases 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- 108010082495 Dietary Plant Proteins Proteins 0.000 description 1
- 208000010228 Erectile Dysfunction Diseases 0.000 description 1
- 241000360590 Erythrites Species 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 241001289529 Fallopia multiflora Species 0.000 description 1
- 206010016352 Feeling of relaxation Diseases 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 208000034507 Haematemesis Diseases 0.000 description 1
- 206010018873 Haemoconcentration Diseases 0.000 description 1
- STECJAGHUSJQJN-GAUPFVANSA-N Hyoscine Natural products C1([C@H](CO)C(=O)OC2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-GAUPFVANSA-N 0.000 description 1
- 241000581650 Ivesia Species 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- 102000004407 Lactalbumin Human genes 0.000 description 1
- 108090000942 Lactalbumin Proteins 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 229920002774 Maltodextrin Polymers 0.000 description 1
- 239000005913 Maltodextrin Substances 0.000 description 1
- 108010011756 Milk Proteins Proteins 0.000 description 1
- 102000014171 Milk Proteins Human genes 0.000 description 1
- 101100503585 Mus musculus Furin gene Proteins 0.000 description 1
- 102000008934 Muscle Proteins Human genes 0.000 description 1
- 108010074084 Muscle Proteins Proteins 0.000 description 1
- 208000029549 Muscle injury Diseases 0.000 description 1
- STECJAGHUSJQJN-UHFFFAOYSA-N N-Methyl-scopolamin Natural products C1C(C2C3O2)N(C)C3CC1OC(=O)C(CO)C1=CC=CC=C1 STECJAGHUSJQJN-UHFFFAOYSA-N 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- 206010053159 Organ failure Diseases 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 241000219050 Polygonaceae Species 0.000 description 1
- 241000222341 Polyporaceae Species 0.000 description 1
- 241000222383 Polyporales Species 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 241001619461 Poria <basidiomycete fungus> Species 0.000 description 1
- 241001282135 Poromitra oscitans Species 0.000 description 1
- 208000019155 Radiation injury Diseases 0.000 description 1
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 1
- 241000576755 Sclerotia Species 0.000 description 1
- 241001558929 Sclerotium <basidiomycota> Species 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 108010073771 Soybean Proteins Proteins 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 229930003451 Vitamin B1 Natural products 0.000 description 1
- 229930003471 Vitamin B2 Natural products 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 229930003448 Vitamin K Natural products 0.000 description 1
- 239000005862 Whey Substances 0.000 description 1
- 108010046377 Whey Proteins Proteins 0.000 description 1
- 102000007544 Whey Proteins Human genes 0.000 description 1
- 241001619454 Wolfiporia Species 0.000 description 1
- 206010048232 Yawning Diseases 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 235000021120 animal protein Nutrition 0.000 description 1
- 230000003712 anti-aging effect Effects 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 210000000702 aorta abdominal Anatomy 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 230000000386 athletic effect Effects 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 235000019658 bitter taste Nutrition 0.000 description 1
- 150000005693 branched-chain amino acids Chemical class 0.000 description 1
- 208000034526 bruise Diseases 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 210000005252 bulbus oculi Anatomy 0.000 description 1
- 108010033929 calcium caseinate Proteins 0.000 description 1
- 230000001914 calming effect Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 210000000748 cardiovascular system Anatomy 0.000 description 1
- 235000021466 carotenoid Nutrition 0.000 description 1
- 150000001747 carotenoids Chemical class 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 235000013339 cereals Nutrition 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- 230000009194 climbing Effects 0.000 description 1
- ASARMUCNOOHMLO-WLORSUFZSA-L cobalt(2+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2s)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+2].[N-]([C@@H]1[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@H](C)OP([O-])(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O ASARMUCNOOHMLO-WLORSUFZSA-L 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 235000008504 concentrate Nutrition 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 229940099112 cornstarch Drugs 0.000 description 1
- 210000004351 coronary vessel Anatomy 0.000 description 1
- 235000020247 cow milk Nutrition 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 239000009524 danshen dripping Substances 0.000 description 1
- 238000005238 degreasing Methods 0.000 description 1
- 230000001066 destructive effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 239000009465 diaoxinxuekang Substances 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 210000002249 digestive system Anatomy 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000008769 eleutheroside Substances 0.000 description 1
- 229930190029 eleutheroside Natural products 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 239000002360 explosive Substances 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 208000035861 hematochezia Diseases 0.000 description 1
- 230000011132 hemopoiesis Effects 0.000 description 1
- 235000019534 high fructose corn syrup Nutrition 0.000 description 1
- 235000012907 honey Nutrition 0.000 description 1
- 201000001421 hyperglycemia Diseases 0.000 description 1
- 230000007954 hypoxia Effects 0.000 description 1
- 230000001146 hypoxic effect Effects 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 208000026278 immune system disease Diseases 0.000 description 1
- 201000001881 impotence Diseases 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 210000005240 left ventricle Anatomy 0.000 description 1
- 230000037356 lipid metabolism Effects 0.000 description 1
- 230000003859 lipid peroxidation Effects 0.000 description 1
- 231100001252 long-term toxicity Toxicity 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 201000007227 lymph node tuberculosis Diseases 0.000 description 1
- 201000004792 malaria Diseases 0.000 description 1
- 239000000845 maltitol Substances 0.000 description 1
- 235000010449 maltitol Nutrition 0.000 description 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
- 229940035436 maltitol Drugs 0.000 description 1
- 229940035034 maltodextrin Drugs 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 235000021239 milk protein Nutrition 0.000 description 1
- 201000002266 mite infestation Diseases 0.000 description 1
- VYQNWZOUAUKGHI-UHFFFAOYSA-N monobenzone Chemical compound C1=CC(O)=CC=C1OCC1=CC=CC=C1 VYQNWZOUAUKGHI-UHFFFAOYSA-N 0.000 description 1
- 210000000663 muscle cell Anatomy 0.000 description 1
- 230000003387 muscular Effects 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 230000000050 nutritive effect Effects 0.000 description 1
- 210000004279 orbit Anatomy 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 206010033675 panniculitis Diseases 0.000 description 1
- 229940055726 pantothenic acid Drugs 0.000 description 1
- 235000019161 pantothenic acid Nutrition 0.000 description 1
- 239000011713 pantothenic acid Substances 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 150000002989 phenols Chemical class 0.000 description 1
- SHUZOJHMOBOZST-UHFFFAOYSA-N phylloquinone Natural products CC(C)CCCCC(C)CCC(C)CCCC(=CCC1=C(C)C(=O)c2ccccc2C1=O)C SHUZOJHMOBOZST-UHFFFAOYSA-N 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 231100000572 poisoning Toxicity 0.000 description 1
- 230000000607 poisoning effect Effects 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 235000021075 protein intake Nutrition 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 235000008151 pyridoxamine Nutrition 0.000 description 1
- 239000011699 pyridoxamine Substances 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 230000000191 radiation effect Effects 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000002040 relaxant effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 210000001034 respiratory center Anatomy 0.000 description 1
- 229960002477 riboflavin Drugs 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 208000001076 sarcopenia Diseases 0.000 description 1
- STECJAGHUSJQJN-FWXGHANASA-N scopolamine Chemical compound C1([C@@H](CO)C(=O)O[C@H]2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-FWXGHANASA-N 0.000 description 1
- 229960002646 scopolamine Drugs 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 230000003860 sleep quality Effects 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- HUAUNKAZQWMVFY-UHFFFAOYSA-M sodium;oxocalcium;hydroxide Chemical compound [OH-].[Na+].[Ca]=O HUAUNKAZQWMVFY-UHFFFAOYSA-M 0.000 description 1
- 229940001941 soy protein Drugs 0.000 description 1
- 229940071440 soy protein isolate Drugs 0.000 description 1
- 235000013599 spices Nutrition 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 230000007103 stamina Effects 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 210000004304 subcutaneous tissue Anatomy 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 235000012976 tarts Nutrition 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 229960003495 thiamine Drugs 0.000 description 1
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 230000035922 thirst Effects 0.000 description 1
- 230000002992 thymic effect Effects 0.000 description 1
- 229940034610 toothpaste Drugs 0.000 description 1
- 239000000606 toothpaste Substances 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 230000002936 tranquilizing effect Effects 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 229940124549 vasodilator Drugs 0.000 description 1
- 239000003071 vasodilator agent Substances 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 235000010374 vitamin B1 Nutrition 0.000 description 1
- 239000011691 vitamin B1 Substances 0.000 description 1
- 235000019164 vitamin B2 Nutrition 0.000 description 1
- 239000011716 vitamin B2 Substances 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 235000019168 vitamin K Nutrition 0.000 description 1
- 239000011712 vitamin K Substances 0.000 description 1
- 150000003721 vitamin K derivatives Chemical class 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 229940046010 vitamin k Drugs 0.000 description 1
- 239000009306 yunnan baiyao Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/40—Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pediatric Medicine (AREA)
- Mycology (AREA)
- Nutrition Science (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
The invention discloses granules with an anti-fatigue and health-care function. The granules are prepared from following main components: 0.1g-5g of creatine, 1g-3g of calcium beta-hydroxy-beta-methyl butyrate, 1g-10g of fructose, 1g-500g of protein powder, 3g-9g of pseudo-ginsengs, 9g-30g of codonopsis pilosula, 10g-15g of radix puerariae, 9g-27g of acanthopanax senticosus, 6g-12g of American ginsengs and 0.1g-1.4g of taurine. The granules with the anti-fatigue and health-care function have the anti-fatigue and health-care function; the malnutrition is improved; the granules have an obvious effect to promote the recovery after exercises.
Description
Technical field
The present invention relates to field of food, especially one has anti-fatigue health-caring function electuary.
Background technology
Fatigue is a kind of subjective uncomfortable sensation, but objectively can be under equal conditions, loses it and completes normal activity or the ability to work be originally engaged in.Antifatigue is exactly to offset the sensation of this fatigue by certain methods means, thereby makes people's feeling relaxed spiritedness.Tired in physiological variation: due to the accumulation of lactic acid and other metabolites, muscle tone declines, and motion durability reduces; Due to the accumulation of carbon dioxide, stimulate respiratory center, also can cause yawning.Over training is one of common disease of sports medical science, affects athletic competitiveness.For the driver of long-distance car, confirmed fatigue affects traffic safety.
Therefore develop a product in antifatigue simultaneously, makeup energy simultaneously, alleviates malnutrition and has very important significance.
Summary of the invention
The present invention addresses the above problem adopted technical scheme: this electuary comprises creatine, beta-hydroxy-Beta-methyl calcium butyrate, fructose, protein powder, pseudo-ginseng, Radix Codonopsis, the root of kudzu vine, wilsonii, American Ginseng, taurine.
Anti-fatigue health-caring function electuary, the weight of described each composition is:
The present invention addresses the above problem adopted technical scheme: this electuary includes creatine, beta-hydroxy-Beta-methyl calcium butyrate, fructose, protein powder, pseudo-ginseng, Radix Codonopsis, the root of kudzu vine, wilsonii, American Ginseng, Poria cocos, taurine.
The weight of each composition of the present invention is,
The present invention addresses the above problem adopted technical scheme: this electuary includes creatine, beta-hydroxy-Beta-methyl calcium butyrate, fructose, protein powder, sanchi leaf, Radix Codonopsis, the root of kudzu vine, wilsonii, American Ginseng, Poria cocos, tuber fleeceflower leaf, taurine.
The weight of each composition of the present invention is,
The present invention addresses the above problem adopted technical scheme: this electuary includes creatine, beta-hydroxy-Beta-methyl calcium butyrate, protein powder, notoginseng polysaccharide, Codonopsis pilosula polysaccharide, pueraria polysaccharide, Radix Et Caulis Acanthopanacis Senticosi polysaccharide, Radix Panacis Quinquefolii polysaccharide, pachymaran, taurine.
The weight of each composition of the present invention is,
The present invention compared with prior art, has following characteristics: this electuary contains creatine, beta-hydroxy-Beta-methyl calcium butyrate, fructose, protein powder, pseudo-ginseng, wilsonii, American Ginseng, Radix Codonopsis, the root of kudzu vine, Poria cocos, taurine.In antifatigue simultaneously, makeup energy, alleviates malnutritive this product.
The present invention compared with prior art, has following characteristics: this electuary contains creatine, beta-hydroxy-Beta-methyl calcium butyrate, fructose, protein powder, sanchi leaf, wilsonii, American Ginseng, Radix Codonopsis, the root of kudzu vine, Poria cocos, tuber fleeceflower leaf, taurine.In antifatigue simultaneously, makeup energy, alleviates malnutritive this product.
The present invention compared with prior art, has following characteristics: this electuary contains creatine, beta-hydroxy-Beta-methyl calcium butyrate, protein powder, notoginseng polysaccharide, Codonopsis pilosula polysaccharide, pueraria polysaccharide, Radix Et Caulis Acanthopanacis Senticosi polysaccharide, Radix Panacis Quinquefolii polysaccharide, pachymaran, taurine.In antifatigue simultaneously, makeup energy, alleviates malnutritive this product.
Above composition is preferably in total amount 1000g.
Constituent analysis
Protein
Protein is one of needed by human nutrient, is the material base of life.Protein can be divided into animal protein and the large class of vegetable protein two by food source.Protein powder meets the theory of current nutrition educational circles Popularization And Development double protein product. the rationally effectively training of protein composition and large load, can change the nutrition of health, and strength and stamina achievement is impacted, the non-nutritive effect of excess ingestion protein is the danger that it is potential.
Creatine
Creatine is the material by arginine, glycine and methionine three seed amino acid synthesizeds.Can be synthetic voluntarily by human body, also can be by absorbing in food.Creatine, is spontaneous a kind of amino acid derivativges in human body, and it can increase muscle strength fast, promotes new flesh to increase, and the recovery that accelerates fatigue, improves explosive force.Creatine stores more in human body, and strength and locomitivity are also stronger.
It not only can Quick energizing quantity, and (Activities of human body are by ATP, be that atriphos provides energy, and the memory space of ATP in human body lacking very, when motion, ATP is approach exhaustion soon, at this moment creatine can be fast more synthetic ATP supplied with energy).Can also increase strength, increase muscle, accelerate fatigue recovery.Human body memory space is more again for creatine, and the supply of energy is just more abundant, fatigue recovery just faster, and kinergety is also just stronger.In the time that physical consumption is larger, human body approximately needs the creatine of 5 grams of left and right every day.But can not meet creatine requirement completely in diet.
Beta-hydroxy-Beta-methyl calcium butyrate
Purposes and the effect of beta-hydroxy-Beta-methyl calcium butyrate: HMB is the metabolite of the basic trace of a kind of human body containing branched-chain amino acid, in the protein of musculature synthesizes, plays an important role, and can promote muscle cell growth, improves body tissue.
Beta-hydroxy-Beta-methyl calcium butyrate is as a kind of novel anabolism nutritional agents of high-intensity exercise person, can make body fat reduce, reduce muscle protein consumption, help muscle recovery and reduce because of the overworked effect that causes muscle damage, can improve exercise intensity and endurance.
Beta-hydroxy-Beta-methyl calcium butyrate is also that agent is excited in a kind of very strong immunity, can strengthen immune function of human body, reduces the effect of cholesterolemia, can reduce disease, anti-aging, build up health, to improve the quality of living. it is mainly as food additives, nutritional supplement, muscle-building agent.
Fructose
Fructose enters after liver, can be transformed into rapidly glucose and add " Cori circulation ": in liver, be converted to glucose → liver glycogen → blood sugar → inose unit → blood lactic acid → liver glycogen.The existence of this important circulation, contributes to body to maintain the normal level of blood sugar; Contribute to the dissipation of the lactic acid of accumulation in motion and make full use of; Contribute to the synthetic again of body liver glycogen and inose unit.
Pseudo-ginseng
Pseudo-ginseng (Panax notoginseng) is araliaceae ginseng plant, it is the traditional rare traditional Chinese medicine of China, for traditional hemostasis good medicine, also be one of main component of Diaoxinxue Kang, compound danshen dripping pills and " Yunnan Baiyao " that has won fame both at home and abroad, the important source material of pseudo-ginseng or daily-use chemical industry high-grade nutrient health care product, as tianqi oral liquid, tianqi toothpaste etc.Sanchi leaf is warm in nature, and taste is pungent, for hemostasis, detumescence, analgesic therapy, control haematemesis, bleeding from five sense organs or subcutaneous tissue, have blood in stool, traumatism and bleeding, carbuncle pyogenic infections sore etc.Compendium of Material Medica claims notoginseng haulm " control injured, fall and put out blood, that applies stops, and bruise is loose through night, the same root of complementary work ".The cauline leaf that research in recent years shows pseudo-ginseng also can hyoscine, and toxic and side effect is little.
The root of kudzu vine
The root of kudzu vine has antifatigue effect and improves the CBF of cardiovascular and cerebrovascular, can make coronary artery and cerebral vasodilators, increase CBF, reduce vascular resistence and the consumption of cardiac muscle to oxygen, increase the supply of blood to oxygen, the cardiac muscle that suppresses to cause because of the deficiency of oxygen produces lactic acid, thereby reaches the effect of antifatigue
Wilsonii
Wilsonii has antifatigue effect.Mouse peritoneal injection wilsonii alcohol medicinal extract aqueous solution 20g, swimming time extends 1/4, and the mouse rope climbing exhaustion time is better than ginsenoside.The antifatigue effect of eleutheroside is stronger than ginsenoside.The comparable control group of acanthopanax extract improves activities in rats amount 70%.
American Ginseng
American Ginseng is to middle-aged and old Organ Failures, immunologic hypofunction, and the endurance that conforms goes down, and has certain guaranteeing role, can strengthen the special defence capability of body to various destructive stimuluses.
The fleece-flower root
Fleece-flower root Polygonum multiflorum Thunb. is polygonaceae plant, and piece root and Ye Junke are used as medicine, and the national most laboratories such as Zhejiang, Jiangsu, Hunan, Guizhou all have product.It is used as medicine with root, has removing toxic substances, the carbuncle that disappears, preventing malaria, effect of relaxing bowel; Be used as medicine with leaf, have that the sore controlled is swollen, effect of mange, scrofula.Archen is the main medicinal ingredient of the fleece-flower root.
Radix Codonopsis
Radix Codonopsis, for conventional bulk medicinal materials, has long applicating history in China, and its nature and flavor are sweet flat, nontoxic, the effect such as have tonifying middle-Jiao and Qi, promote the production of body fluid to quench thirst.Modern pharmacology studies confirm that, Radix Codonopsis to cardiovascular system, blood and hematopoiesis function, digestive system, body's immunity, delay senility and all can play corresponding pharmacological action.
Poria cocos
Poria cocos Poria cocos (Schw.) Wolf claim again Fu Tu, Fu spirit, Yun Ling, Song Ling etc., belongs to Aphyllophorales Aphyllophorales on taxology, Polyporaceae Polyporaceae, and Poria cocos belongs to Wolfiporia.Mainly be distributed in the provinces such as Yunnan, Hubei, Anhui, Shandong, Hebei, Henan.Its dry sclerotia is called " PORIA ALBA ", and the crust of sclerotium is fuling peel.Recorded by going through version " Chinese pharmacopoeia ".Poria cocos is the traditional Chinese medicine of China, and its property is flat, and taste is sweet, light, the thoughts of returning home, lung, spleen, kidney channel; The effect with clearing damp and promoting diuresis, invigorating the spleen bowl spares, calming heart and tranquilizing mind, is the raw material of multiple prescription and Chinese patent drug, has " ten medicine nine Poria cocos " to say.
Taurine
According to the Ministry of Public Health " health food inspection and assessment technique specification "; mouse is divided into basic, normal, high dosage group and negative control group at random, gives continuously with taurine after 30 days, detect mice burden swimming time-to-live and serum urea; hepatic glycogen, the content of blood lactic acid.Result mice burden swimming prolonged survival period, serum urea content and blood lactic acid TG-AUC reduce, and the content of hepatic glycogen increases.Conclusion, taurine has the effect of alleviating mouse physical fatigue.
Prescription analysis
The growth that the present invention adopts creatine, beta-hydroxy-Beta-methyl calcium butyrate, protein powder to supplement protein, improves promoting blood circulation and removing blood stasisly with Tong Xinmai by pseudo-ginseng, wilsonii, American Ginseng, the cooperation of above two groups of materials can be played the positive effect of holding up that consolidates,
Carried out tonifying middle-Jiao and Qi, promoted the production of body fluid and stomach by Radix Codonopsis, the root of kudzu vine, this group material plays the effect of enriching yin mild laxation.
By Poria cocos, fleece-flower root invigorating spleen to remove dampness with the peaceful mind, the effect that this group material plays scattered silt opens knot
Therefore, the mechanism of action of full side be hold up sun consolidate, promoting blood circulation and removing blood stasis, enriching yin mild laxation, from the angle of doctor trained in Western medicine, the present invention can contribute to realize following one or more objects: nutrition is provided, maintains the lean body mass amount in the elderly of Sarcopenia, recover muscle strength, improve muscle strength, thereby play on the whole raising immunity of organisms, the effect of antifatigue.
The crowd of being suitable for
Product of the present invention is applicable to the long-term crowd in the high deficiency of Yin state of sun such as sportsman, driver, teacher, clerical workforce, and develops the product of three technical schemes, is below the concrete analysis of these three technical schemes.
Be suitable for crowd's non-diabetic people's technical scheme, wherein contain fructose
The weight of each composition of the present invention is,
In this technical scheme, Poria cocos is selectable composition.
Be suitable for not high crowd's technical scheme of crowd's non-diabetic, sleep quality, wherein contain fructose
The weight of each composition of the present invention is,
In this technical scheme, Poria cocos, tuber fleeceflower leaf are selectable compositions.
Be suitable for disorders of lipid metabolism syndrome crowd's technical scheme, wherein do not contain fructose
The weight of each composition of the present invention is,
Selective composition of the present invention
The non-limiting composition of this optional member comprises anticorrisive agent, antioxidant, emulsifying agent, buffer, nutrients, colouring agent, spices, thickener and stabilizing agent etc.
The non-limiting composition of this optional member can further comprise vitamin or relevant nutrients, and its limiting examples comprises VitAVitE, vitamin B2, pyridoxamine, cobalamin, vitamin K, biotin, vitamin C, vitamin B1, carotenoid, folic acid, pantothenic acid, nicotinic acid, choline, salt and its derivative and its combination.
Non-limiting composition, the especially fructose of this optional member can also substitute with suitable carbohydrate: the starch of maltodextrin, hydrolysis or sex change or cornstarch, glucose polymer, corn syrup, corn-syrup solids, derivative carbohydrate, glucose, fructose, lactose, high-fructose corn syrup, honey, sugar alcohol (for example maltitol, erythrite, sorbierite) and its combination of rice.
For the suitable protein powder of nutritional-based product, comprising: the albumen of hydrolysis, partial hydrolysis or non-hydrolysis or protein sources, it can be obtained by any source known or that other is suitable, for example milk (for example, casein, whey), animal (for example, meat, fish), cereal is (for example, paddy, corn), vegetables (for example, soybean or pea) or its combination.The limiting examples of this albumen comprises: lactoprotein separator, concentrated milk protein, casein separator, lactalbumin, casein sodium or calcium caseinate, full cow's milk, the partially or completely milk of degreasing, soy protein isolate, soy protein concentrate.
Formulation of the present invention
Product of the present invention is through sterilization treatment.The formulation of oral formulations of the present invention: comprise tablet, pulvis, granule, emulsion, syrup, capsule etc., be preferably pulvis, tablet and granule.
Auxotype solid, can take the directly auxotype powder of mixing, spray-dired auxotype powder,
Spraying drying steps also can comprise any known or other spray drying technology that is suitable for preparing auxotype powder.
A kind of method of preparation spraying dry nutritional type powder comprises: form aqueous slurry or liquid, and by its homogenizing, then, by dry to these slurries or liquid spraying, prepare spray-dired auxotype powder.The method may further include the following step: spraying is dry, is dry mixed, or in addition extra nutrition composition is joined in this spray-dired auxotype powder.
Purposes of the present invention
Product of the present invention, it is for preventing or improving the symptom being caused by fatigue.It for the symptom being caused by fatigue is: shoulder is stiff, be afraid of cold, erectile dysfunction, easily divert attention, at least one symptom of doze, immune disorder, metabolism of blood glucose imbalance, ammonia metabolism imbalance.
Detailed description of the invention
Specific embodiment 1
Product of the present invention is by weight forming with following compositions
Above composition is mixed and stirred, dry, sterilizing, both.
Specific embodiment 2
Product of the present invention is by weight forming with following compositions
Above composition is mixed and stirred, dry, sterilizing, both.
Specific embodiment 3
Product of the present invention is by weight forming with following compositions
Above composition is mixed and stirred, dry, sterilizing, both.
Specific embodiment 4
Product of the present invention is by weight forming with following compositions
Above composition is mixed and stirred, dry, sterilizing, both.
Specific embodiment 5
Product of the present invention is by weight forming with following compositions
Above composition is mixed and stirred, dry, sterilizing, both.
Specific embodiment 6
According to " Chinese medicine, natural drug studies on acute toxicity technological guidance principle " studies on acute toxicity.Adopt Kunming mouse, male and female half and half.Fasting 12 hours before experiment, according to 5 groups, 10/group of tested group of mouse is with maximum dosage gavage according to the solution of specific embodiment 1-5 product, and the morning and evening is respectively once; Control group gavage equivalent physiological saline.Observe body weight, diet, outward appearance, behavior, secretion, excretion, the poisoning and death condition of each group of mouse, Continuous Observation 14 days.Result shows, the specific embodiment 1-5 product maximum dosage-feeding scope of the mouse of 2 gastric infusions on the 1st is 263.23-319.38g/kg, and mouse occurs without acute toxic symptoms, and histoorgan, without pathology, illustrates that Product Safety of the present invention is good, and toxic and side effect is low.
Be diluted with distilled water into the suspension of concentration as 40.0g/ml and 20.0g/ml (not containing the powder of auxiliary material) taking specific embodiment 1-5 product, as large and small dosage group trial drug, according to 5 groups, each 10 of the rat of male and female half and half/group is gavaged to 3 months continuously, carry out long term toxicity test, non-toxic symptom occurs, and histoorgan is without pathology, illustrate that Product Safety of the present invention is good, toxic and side effect is low.
The cardiovascular effect of specific embodiment 7 product anti-oxidation protection of the present invention
Normal group: get male SD normal rat in 10 week age (220-240 gram), by catheter retaining in the jugular vein of normal rat.
Model group: male SD in 10 week age (220-240 gram) sets up isoprel induction treating myocardial ischemia damage model.By catheter retaining in the jugular vein of rat model.
Rat model and normal rat are all raised 3 days in advance, and average mark in groups.Every group 10.
Under fasted conditions not, give the aqueous solution of the 1st group of normal rat oral protein powder, 200mg/kg.
Under fasted conditions not, give the 2nd group model rat aqueous solution of oral " protein powder+beta-hydroxy-Beta-methyl calcium butyrate+creatine " simultaneously, wherein " protein powder+beta-hydroxy-Beta-methyl calcium butyrate+creatine " is 200mg/kg, 1.5mg/kg, 2.5mg/kg after converting ".
Give the aqueous solution of the powder of 3-7 group model Oral Administration in Rats specific embodiment 1-5, wherein " protein powder+beta-hydroxy-Beta-methyl calcium butyrate+creatine " is 200mg/kg, 1.5mg/kg, 2.5mg/kg after converting ".
Before taking medicine, and take medicine latter 30 minutes, 1,3,6,12 hour, collect urine, detect the content of urea nitrogen.
After 12 hours, with after through abdominal aorta blood drawing, point 2 pipes are collected respectively blood plasma and serum.All rat is put to death, and opens chest, wins heart, in 4 DEG C of physiological saline, washes away bloodstain, blots excessive moisture, weighs cardiac mass.The heart that does pathology is put into 4% paraformaldehyde and is fixed; Cut part left ventricle antetheca cardiac muscle, by weight adding physiological saline to prepare 10% homogenate at 1: 9,3000r/min, 4 DEG C of centrifugal supernatants that go are to be measured.Survey superoxide dismutase (SOD), MDA (MDA), TAC (T-AOC).
The variation of urea nitrogen concentration
Interpretation of result:
In 3-7 group, give the product of specific embodiment 1-5, compared with the 2nd group with the 1st group, the maximum drug concentration (C of urea nitrogen
max) significantly reduce and maximum drug concentration time (T
max) shorten.Under the haemoconcentration-time graph of urea nitrogen, area significantly dwindles.Therefore, product of the present invention is conducive to reduce the various side effects that hyperproteosis causes nitrogen metabolism imbalance.
ISO is caused to the impact of Acute Myocardial Ischemia Rats myocardium lipid peroxidation
The impact of the product of specific embodiment 1-5 on the SOD of cardiac muscular tissue, MDA and T-AOC value (x ± s)
| Grouping | SOD | MDA | T-AOC |
| ? | U／ml | nmol／ml | U／ml |
| The 1st group | 312.37±11.53 | 1.25±0.31 | 23.52±2.75 |
| The 2nd group | 258.12±22.45 | 2.41±0.24 | 18.31±2.17 |
| The 3rd group | 261.25±21.70 | 3.12±0.23 | 15.12±0.24 |
| The 4th group | 278.42±28.53 | 2.52±0.69 | 13.21±0.21 |
| The 5th group | 285.52±31.23 | 2.32±0.17 | 12.53±0.12 |
| The 6th group | 273.25±41.26 | 2.31±0.29 | 12.36±0.51 |
| The 7th group | 263.28±33.12 | 2.22±0.28 | 10.12±0.45 |
Specific embodiment 8 product of the present invention can strengthen endurance
The resistance to anoxic experiment of mouse normal pressure
1, animal used as test
Kunming mouse, male, 20-22 gram, 10 every group, look for food and the freedom of drinking water, room temperature (25 ± 2) DEG C, natural lighting.
2, experimental technique
The resistance to anoxic experiment of mouse normal pressure: the continuous gavage of mouse 7 days, every day 2 times, after mouse last gavage 4h, mouse is placed in respectively to the airtight wide-mouth bottle of 250ml that soda lime 7.5g is housed, after sealing, its time-to-live of observed and recorded, taking breath stopped as dead indication.
Gavage method:
Blank group, gives the physiological saline with drug study group equivalent;
Positive controls, the aqueous solution 2ml of oral " protein powder+beta-hydroxy-Beta-methyl calcium butyrate+creatine " simultaneously, wherein " protein powder+beta-hydroxy-Beta-methyl calcium butyrate+creatine " is " 20mg/kg, 0.15mg/kg, 0.25mg/kg " after converting.
Embodiment 1-5 product group, gives the product 2ml of embodiment 1-5 product, and wherein " protein powder+beta-hydroxy-Beta-methyl calcium butyrate+creatine " is " 20mg/kg, 0.15mg/kg, 0.25mg/kg " after converting.
Experimental result:
On the impact of the resistance to the survival time under hypoxic condition of mouse normal pressure, in Table, compared with control group, embodiment of the present invention 1-5 organizes tested mouse fur light, usually more active, and none animal dead can significantly improve mouse normal pressure hypoxia-bearing capability.
Specific embodiment 9 product of the present invention can strengthen muscle power
Mice burden swimming experiment
1, animal used as test
Kunming mouse, male, 20-22 gram, 10 every group, look for food and the freedom of drinking water, room temperature (25 ± 2) DEG C, natural lighting.
2, experimental technique
The resistance to anoxic experiment of mouse normal pressure: the continuous gavage of mouse 7 days, every day 2 times, after mouse last gavage 4h, every group of 10 mouse, are one to be the weight of its weight 5% at every mouse tail, put into the swimming trunk went swimming of 110cm × 60cm × 70cm, depth of water 20cm, water temperature is 30 ± 0.5 DEG C, all enters the lasting 8s of water can not emerge as judging terminal with mouse head, when record swimming exhaustion, asks.
Gavage method:
Blank group, gives the physiological saline with drug study group equivalent;
Positive controls, the aqueous solution 2ml of oral " protein powder+beta-hydroxy-Beta-methyl calcium butyrate+creatine " simultaneously, wherein " protein powder+beta-hydroxy-Beta-methyl calcium butyrate+creatine " is " 20mg/kg, 0.15mg/kg, 0.25mg/kg " after converting.
Embodiment 1-5 product group, gives the product 2ml of embodiment 1-5 product, and wherein " protein powder+beta-hydroxy-Beta-methyl calcium butyrate+creatine " is " 20mg/kg, 0.15mg/kg, 0.25mg/kg " after converting.
Compared with control group, embodiment of the present invention 1-5 product can significantly improve mice burden swimming ability.
Specific embodiment 10 product of the present invention regulates immune effect
Get the Kunming mouse of age in 8-10 week, body weight 18-20g, male
Be divided at random: Normal group (gavage physiological saline),
Positive controls, the aqueous solution 2ml of oral " protein powder+beta-hydroxy-Beta-methyl calcium butyrate+creatine " simultaneously, wherein " protein powder+beta-hydroxy-Beta-methyl calcium butyrate+creatine " is " 20mg, 0.15mg, 0.25mg " after converting.
Embodiment 1-5 product group, gives the product 2ml of embodiment 1-5 product, and wherein " protein powder+beta-hydroxy-Beta-methyl calcium butyrate+creatine " is " 20mg/kg, 0.15mg/kg, 0.25mg/kg " after converting.
After 7 days, except Normal group mouse, all the other are respectively organized mouse and carry out
60co gamma-radiation, dosage is 5Gy.After irradiation, each group continues the corresponding solution of gavage, then tests on the same day.Immunity is extremely sensitive to radiation injury, and radiation effects can make the each part of immune system occur inhibition effect in body.
Get
60the each group of mouse of 7 days after Co gamma-radiation, weigh, eye socket is got blood and is put to death, divide and get thymus gland and spleen, weigh, calculate respectively thymus index and index and spleen index by following formula: thymus index=thymic weight (mg)/mouse weight (g), index and spleen index=spleen weight (mg)/mouse weight (g), respectively organizes data and represent with means standard deviation.
The results are shown in Table, the Thymus and Spleen index of radiation model group mouse is all lower than Normal group, and difference has conspicuousness (p<0.01); Positive drug group, embodiment 1-5 product group can raise
60the Thymus and Spleen index of Co γ radiation murine; there is significant difference (p<0.05) compared with radiation model group; illustrate that radiation resistant composition has protective effect to immune organ, and, the protection more remarkable effect of embodiment 1-5 product group.
Embodiment 1-3 product group pair
60the impact of Co γ radiation murine thymus index, index and spleen index
The impact of specific embodiment 11 product of the present invention on alloxan hyperglycaemia mouse blood sugar
Choose the Kunming mouse of getting age in 8-10 week, body weight 18-20g, male and female half and half, survey on an empty stomach 10h blood sugar 2 times, and interval, after 2 days, is left and taken 10 mouse and made blank, the equal iv alloxan of all the other animals 80mg moulding.After moulding 48h, measure blood sugar.
Choose blood sugar and supply test higher than the mouse of 10mmol/L, be divided at random 8 groups, 10 every group, successive administration 7 days, 1h after last medicine, eyeball rear vein beard is got blood, and separation of serum is measured serum glucose.
Positive controls, the aqueous solution 2ml of oral " protein powder+beta-hydroxy-Beta-methyl calcium butyrate+creatine " simultaneously, wherein " protein powder+beta-hydroxy-Beta-methyl calcium butyrate+creatine " is " 20mg/kg, 0.15mg/kg, 0.25mg/kg " after converting.
Embodiment 1-5 product group, gives the product 2ml of embodiment 1-5 product, and wherein " protein powder+beta-hydroxy-Beta-methyl calcium butyrate+creatine " is " 20mg/kg, 0.15mg/kg, 0.25mg/kg " after converting.
The taste of specific embodiment 12 products of the present invention
Analyzed the intensity of the various tastes of embodiment 1-6 sample by trained sense organ group: sweet taste, saline taste, tart flavour, bitter taste, flavor strength, base strength and phenols.Specifically, once prepare embodiment 1-6 sample, the member of 5 trained panels carries out taste evaluation.After using each embodiment 1-6 sample, embodiment 1-6 sample is all to possess medium sweet taste, the product of medium fragrance.
Claims (2)
1. an anti-fatigue health-caring function electuary, is characterized in that:
Above composition is mixed and stirred, and dry, sterilizing, to obtain final product.
2. an anti-fatigue health-caring function electuary, is characterized in that:
Above composition is mixed and stirred, and dry, sterilizing, to obtain final product.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310754441.6A CN103704711B (en) | 2013-12-31 | 2013-12-31 | Granules with anti-fatigue and health-care function |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310754441.6A CN103704711B (en) | 2013-12-31 | 2013-12-31 | Granules with anti-fatigue and health-care function |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN103704711A CN103704711A (en) | 2014-04-09 |
| CN103704711B true CN103704711B (en) | 2014-12-10 |
Family
ID=50398382
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201310754441.6A Active CN103704711B (en) | 2013-12-31 | 2013-12-31 | Granules with anti-fatigue and health-care function |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103704711B (en) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108606269B (en) * | 2018-04-12 | 2021-08-31 | 昆明邦宇制药有限公司 | Sports nutritional supplement and preparation method thereof |
| CN108813504A (en) * | 2018-05-15 | 2018-11-16 | 哈尔滨工业大学 | A kind of antifatigue soup drink of the dedicated resisting stress of emergency disaster relief personnel and preparation method thereof |
| CN109198520A (en) * | 2018-10-13 | 2019-01-15 | 赤峰禾士营养食品科技有限公司 | A kind of composite nutrient with muscle-increasing function is good for flesh powder and preparation method thereof |
| CN112826839A (en) * | 2019-11-22 | 2021-05-25 | 深圳市药欣生物科技有限公司 | Solid powder composition of plant traditional Chinese medicinal materials and preparation method thereof |
| CN111228468A (en) * | 2020-01-14 | 2020-06-05 | 浙江赛沛力运动科技有限公司 | Liquid preparation with effects of improving exercise endurance and helping exercise recovery |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1631247A (en) * | 2005-01-20 | 2005-06-29 | 北京科信必成医药科技发展有限公司 | Health food with hypoxia preventing and anti-fatigue function and preparation technique thereof |
| CN1685970A (en) * | 2005-04-06 | 2005-10-26 | 云南白药集团股份有限公司 | Health protection food for antifatigue and raising oxygen deficiency tolerance |
| CN101574146A (en) * | 2008-05-07 | 2009-11-11 | 北京康比特体育科技股份有限公司 | Sports nutritional supplement containing HMB |
| CN101785566A (en) * | 2010-01-22 | 2010-07-28 | 北京康比特体育科技股份有限公司 | Sports beverage containing HMB |
| CN102948751A (en) * | 2012-11-23 | 2013-03-06 | 乔德京 | Ginseng tuckahoe acanthopanax senticosus capsule |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040120983A1 (en) * | 2002-12-23 | 2004-06-24 | Philip Connolly | Nutritional supplement |
-
2013
- 2013-12-31 CN CN201310754441.6A patent/CN103704711B/en active Active
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1631247A (en) * | 2005-01-20 | 2005-06-29 | 北京科信必成医药科技发展有限公司 | Health food with hypoxia preventing and anti-fatigue function and preparation technique thereof |
| CN1685970A (en) * | 2005-04-06 | 2005-10-26 | 云南白药集团股份有限公司 | Health protection food for antifatigue and raising oxygen deficiency tolerance |
| CN101574146A (en) * | 2008-05-07 | 2009-11-11 | 北京康比特体育科技股份有限公司 | Sports nutritional supplement containing HMB |
| CN101785566A (en) * | 2010-01-22 | 2010-07-28 | 北京康比特体育科技股份有限公司 | Sports beverage containing HMB |
| CN102948751A (en) * | 2012-11-23 | 2013-03-06 | 乔德京 | Ginseng tuckahoe acanthopanax senticosus capsule |
Non-Patent Citations (1)
| Title |
|---|
| 杨文领，等.抗疲劳中药制剂对游泳小鼠抗疲劳效果观察.《解放军预防医学杂志》.2006,第24卷(第3期),第196-197页. * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN103704711A (en) | 2014-04-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103893549B (en) | A kind of Chinese medicine composition of fatigue alleviating and its production and use | |
| CN102172269B (en) | Hidegelatin fabricated food with beautification function | |
| CN107581619A (en) | A kind of antifatigue anti senility sea cucumber oyster peptide complex capsule and preparation method thereof | |
| TWI721248B (en) | Anti-fatigue composition used for increasing endurance performance | |
| CN104366647A (en) | Composition capable of enhancing durability and relieving fatigue and preparation method of composition | |
| CN101248873A (en) | Drinking food product with sight protection function | |
| CN107691952A (en) | A kind of resisting kinetic fatigue, the composition for promoting postexercise recovery and preparation method thereof | |
| CN103704711B (en) | Granules with anti-fatigue and health-care function | |
| CN101579120A (en) | Nutritional food with weight-losing function and preparation method thereof | |
| CN111035649B (en) | NMN + GLP compound nutritional supplement and preparation method and application thereof | |
| CN105686006A (en) | Oyster compound functional food and preparation method thereof | |
| CN101253903A (en) | Health food and its preparation with fat-reducing function | |
| CN103271346A (en) | Health-care food for relieving physical fatigue | |
| CN110547470A (en) | A nutritional composition for improving male sexual function, and its preparation method | |
| CN107455625A (en) | A kind of nutrient for plants beverage and its preparation technology with antifatigue weight losing function | |
| CN104305453A (en) | American ginseng compounded anti-fatigue sports health beverage | |
| CN107853517B (en) | A kind of Chinese medicinal beverage for refreshing and anti-fatigue and preparation method thereof | |
| CN107212401A (en) | Composition for relieving physical fatigue and its preparation and preparation method | |
| CN101574151A (en) | Nutritional food with function of strengthening immunity and preparation method thereof | |
| CN105341606A (en) | Fatigue preventing and immunity strengthening maca health-care drink and preparation method thereof | |
| CN102657304B (en) | Health-care food with double functions of promoting digestion and relieving physical fatigue | |
| CN101606703A (en) | A kind of nutraceutical and preparation method thereof with antihypertensive function | |
| CN109528904A (en) | A kind of kidney-tonifying health-care, boosting qi and nourishing yin, pharmaceutical composition of high-content ginsenoside and preparation method thereof | |
| CN105433382B (en) | A kind of maca composition and its preparation method and application | |
| CN104839846A (en) | Ginseng functional health sports drink and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C41 | Transfer of patent application or patent right or utility model | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20151217 Address after: 100176, No. 5, building 2, No. 22, Zhonghe street, Beijing economic and Technological Development Zone, Beijing Patentee after: BEIJING KANG LISHENG PHARMACEUTICAL TECHNOLOGY DEVELOPMENT CO., LTD. Address before: 100176 No. 22 Zhonghe street, Beijing economic and Technological Development Zone, Beijing Patentee before: Cheng Gang |